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Abstract
It is beyond dispute that elevated intraocular pressure (IOP) is a major risk factor for the 
development of primary open angle glaucoma (POAG). Nonetheless, only a minority of patients 
with elevated IOP generate the disease. This leads to the notion that POAG is a progressive optic 
neuropathy caused by added factors that may work in concert with elevated IOP. Corneal 
viscoelastic resistance and vascular autoregulation have been associated to the effects of elevated 
IOP. This article discusses investigational facts suggesting that altered corneal viscoelastic/elastic 
properties and vascular dysregulation may contribute to the development of POAG in patients 
with elevated IOP.
© 2009 Spanish General Council of Optometry. Published by Elsevier España, S.L. All rights reserved.
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Alteración de la biomecánica corneal y disfunción de la autorregulación: 
factores que posiblemente contribuyen al desarrollo de glaucoma primario 
de ángulo abierto en pacientes con presión intraocular elevada
Resumen
Es indiscutible que la presión intraocular (PIO) elevada es un factor de riesgo importante para el 
desarrollo de glaucoma primario de ángulo abierto (GPAA). Sin embargo, la enfermedad aparece 
solamente en una minoría de pacientes con PIO elevada, de lo que se deduce que el GPAA es una 
neuropatía óptica progresiva causada por factores añadidos que posiblemente actúan junto con la 
PIO elevada. La resistencia viscoelástica de la córnea y la autorregulación vascular se han asocia-
Altered corneal biomechanics and autoregulation dysfunction 207
Introduction
Glaucoma is a leading cause of preventable blindness in the 
world. The complete understanding of the pathogenesis of 
the disease is still very much in debate. Nonetheless, as 
studies have evolved, elevated intraocular pressure (IOP) 
has been looked at differently in regards to its contribution 
to the development of primary open-angle glaucoma 
(POAG). It is now considered by some researchers as a 
signiÀ cant risk factor that may be inÁ uenced by viscoelastic 
and elastic properties of the cornea. 1 Furthermore, corneal 
viscoelastic resistance and vascular autoregulation have 
been associated to the effects of elevated IOP. 2,3 Others 
with a different perspective suggest that the effect of 
elevated IOP on the optic nerve head may be at the expense 
of autoregulatory mechanisms in the oculo-vascular system. 4 
Conceivably, the possible association of these two factors to 
elevated IOP may help clarify the reason(s) for clinical 
differences between patients with POAG and patients with 
ocular hypertension (OHT).
Ocular rigidity has been characterized in part by 
viscoelastic and elastic properties of the cornea. 
Measurement of these properties is obtained with the ocular 
response analyzer (ORA). This instrument is a sophisticated 
non-contact pneumo-tonometer (Reichert Ophthalmic 
Instruments, Buffalo NY, USA) that records two applanation 
pressure measurements from the air pulse delivered to the 
cornea. One at the applanation point as the cornea is moved 
inward and another at the applanation point as it moves 
outward to its original contour. The difference between 
these two measurements is termed corneal hysteresis (CH) 
(Figure 1). CH deÀ nes the viscoelastic behavior of the cornea 
in response to air applanation force. 5 This viscoelastic 
response reÁ ects the capacity of the cornea to dissipate air 
pulse energy delivered by the pneumo-tonometer, 6 and 
appears to be a dynamic resistance element to the outward 
force exerted by IOP. CH also provides the basis for another 
ORA parameter called corneal resistance factor (CRF). CRF 
is a measurement that may better reflect the elastic 
properties of the cornea. 7 Corneal elasticity relates to the 
res i stance encountered by the a i r  pulse of  the 
pneumo-tonometer while deforming the corneal surface 6 
and seems to be a marker that relates more speciÀ cally to 
the overall ocular structural resistance.
Autoregulation is a process in which normal blood Á ow is 
maintained in response to changes in perfusion pressure. At 
the eye, perfusion pressure (PP) may be generally expressed 
as the difference between the blood pressure (BP) and the 
IOP. 8 So, in essence any significant elevation in IOP will 
reduce perfusion pressure to the eye. 8,9 This effect in turn 
may result in a reduction in blood Á ow to the optic nerve 
head (ONH). Nonetheless, only about 20 percent of patients 
that have persistent elevated IOP develop glaucomatous 
ONH damage. 10 An apparent reason for this is that 
autoregulation impedes the process. As it occurs in other 
organs of the human body, ocular autoregulation maintains 
normal blood flow to the eye in response to changes in 
perfusion pressure by altering mechanical or chemical 
physiologic processes that inÁ uence the tone of blood vessel 
walls; thereby modifying vascular resistance. As the equation 
below shows, blood Á ow (BF) equals PP (PP, Pa — Pv), over 
vascular resistance (R). 11
BF = Pa — Pv
        R
PP at the eye may also be expressed as the difference 
between the perfusion pressure in arteries entering the eye 
and perfusion pressure of veins exciting the eye. PP at the 
venous system exiting the eye needs to be slightly higher or 
equal to the IOP; otherwise a venous collapse may occur. 10 
Thus, an increment in venous perfusion pressure provoked 
by elevated IOP may result in a decrease in ocular PP. 
SigniÀ cant elevated IOP and a resultant decrease in ocular 
PP may challenge or adversely affect ocular vascular 
regulatory function. 12 Furthermore, instability in ocular 
blood Á ow (OBF) may ensue when autoregulation dysfunction 
is present. 12 This may lead to ischemic glaucomatous damage 
to the ONH and retinal ganglion cell (RGC) death, which in 
turn, may partially lead to further regulatory dysfunction 12 
(Figure 2).
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do con los efectos de la PIO elevada. En este artículo se abordan hechos en investigación que in-
dican que la alteración de las propiedades viscoelásticas/elásticas de la córnea y la desregulación 
vascular pueden contribuir al desarrollo de GPAA en pacientes con PIO elevada.
© 2009 Spanish General Council of Optometry. Publicado por Elsevier España, S.L. Todos los derechos 
reservados.
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Discussion
Corneal biomechanics
Statistical analysis exposing the relationship between CH 
and central corneal thickness (CCT), and CRF and CCT in 
OHT and POAG eyes revealed to be proportional. 3 In other 
words, the higher the CCT, the higher the CH and CRF. 
Although the analysis proved to be statistically signiÀ cant, 
the correlation coefÀ cient was not very strong. This may 
imply that CH and CRF are related to CCT but are different 
corneal biomechanical values to assess ocular rigidity. 
Besides this relationship showing a positive effect, data also 
demonstrates that CH and CRF values tend to be greater in 
OHT patients. Shah et al. 3 demonstrated that in a group of 
216 eyes with POAG and 199 with OHT, the latter group had 
statistically significant higher CH and CRF values. 
Sullivan-Mee et al. 13 also revealed in their study that OHT 
subjects had higher mean CH and CFR values than the POAG 
group.
In addition, a relationship of CH and CRF with the 
development and progression of glaucoma is seen. Luce 
and Taylor 6 state that the Ocular Hypertension Treatment 
Study (OHTS), and other studies on the subject, point out 
the significance of CCT in diagnosing and managing the 
progression of glaucoma. Data of these studies rightfully 
imply that low CCT may be a risk factor for the development 
and the progression of glaucoma. Likewise, studies 
assessing CH and CRF values obtained with the ORA 
insinuate this type of relationship. Anand et al. 14 found in 
their study that asymmetric POAG was associated with 
asymmetry in ORA measurements. Hence, lower CH values 
were linked to more advanced forms of POAG and had a 
positive correlation with advanced visual field loss. 
Moreover, Luce and Taylor 6 found that compared to normal 
patients POAG patients had lower than average CH and 
CRF values. However, it is worth noting that in this study 
POAG eyes showed a negative correlation between CH and 
CRF values related to sustained elevated IOP. The eyes 
with severely elevated pressures had much lower than 
average CH values and higher CRF values. Alternatively, 
this may imply that a sustained elevated IOP in POAG 
results in a decreased dynamic resistance and stiffer 
elastic behavior of the cornea. Understandably, increased 
corneal stiffness can be expected at signiÀ cantly elevated 
IOP 6 since the cornea forms part of the overall structural 
rigidity of the eye. Utilizing Friedenwald equation for 
ocular rigidity in their study, Hommer et al. 15 found that 
the corneal stiffness was significantly higher in POAG 
patients than in normal patients. It should be noted, 
however, that the structural rigidity of the eye cannot be 
attributed to corneal properties alone. Biomechanical 
properties of the sclera, choroid, Bruch’s membrane, and 
retina also play an imperative role in the overall rigidity of 
the eye. 15
Autoregulation
Albeit the precise mechanism is not fully understood, it is 
generally accepted that vascular autoregulation ensures 
adequate irrigation to the ONH. 16 Research literature and 
clinical studies on OBF suggest that ocular PP decreases in 
response to elevated IOP and ischemic insult to the ONH 
may arise in the presence of autoregulatory dysfunction. 16,17 
Consequently, this may lead to glaucomatous ONH damage 
and RGC death. 17-20 Research data suggest that abnormalities 
in lipid metabolism, primary vasospastic syndrome, and 
vascular endothelial dysfunction may be responsible for 
ocular circulatory differences and ONH susceptibility in 
response to elevated IOP. 12,17,21
Atherosclerosis
Atherosclerosis is a chronic, progressive vascular disease 
that may reduce the autoregulatory capacity of the optic 
disc. 22 The occurrence of atherothrombosis in this disease 
may lead to impediment of BF. In a study performed on 
monkeys, Faraci et al. 23 found that atherosclerosis increases 
the response of vascular endothelial cells for the activation 
of leukocytes and platelets. Extracellular transduction 
signaling provoking abnormalities in endothelial cell function 
appears to be the triggering mechanism for thrombus 
formation. 24 Moreover, altered serotonin released by 
endothelial cells seems to play an active role in the 
impediment of BF. Hayreh et al. 22 demonstrated in their 
study on atherosclerotic monkeys that the presence of 
serotonin during atherothrombotic pathogenesis induced 
vasospasm of the central retinal artery and posterior ciliary 
artery, consequently impairing BF. However, a cause-effect 
relationship between atherosclerosis and POAG has not been 
proven. In fact, the prospective, population-based 
Rotterdam Eye Study found atherosclerosis not to be a 
signiÀ cant risk factor for POAG. 25
Elevated ocular 
IOP
Decreased 
Perfusion PP
Challenged/dysfunctional
autoregulation
Unstable/Decreased OBF
Ischemic insult
Glaucoma
ONH damage
RGC death
Figure 2 Schematic representation of the contribution of 
autoregulation dysfunction to glaucomatous damage in 
association to elevated IOP. 
IOP: intraocular pressure; PP: perfusion pressure; OBF: ocular 
blood Á ow; ONH: optic nerve head; RGC: retinal ganglion cell. 
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Nevertheless, as a systemic process, atherosclerosis has 
recognized association with vascular conditions that have a 
possible correlation with POAG. For example, atherosclerosis 
is the most common pathologic process affecting the carotid 
system that leads to cerebrovascular accidents. 26 It also 
shows a trend of high prevalence among patients with aortic 
valve stenosis that have experienced episodes of myocardial 
infarction. 27 Both of these conditions have been 
demonstrated to have a relatively strong association with 
POAG. 20,28,29
In brief, atherosclerosis appears to have some inÁ uence 
on OBF. It also appears to play a role in autoregulatory 
dysfunction of vascular conditions that have potential 
association with POAG. However, further investigation is 
necessary to comprehend how endothelial pathophysiology 
in atherosclerosis relates to ocular autoregulatory 
dysfunction in POAG.
Vasospasm
Vasospasm is a reversible, exaggerated constriction or 
closure of blood vessels that leads to excessive reduction in 
BF. 30,31 This excessive vasoconstriction usually results in 
insufÀ cient oxygen supply to the surrounding tissue. 31 Many 
vasospastic episodes arise secondary to underlying diseases 
such as prinzmetal’s angina and multiple sclerosis. 32 However, 
a primary vasospastic syndrome has also been identiÀ ed in 
patients having such a predisposition when exposed to cold 
stimuli and emotional stress. 33 These patients often suffer 
episodes of ocular vasopasm as well as other systemic 
vasospasmic manifestations such as cold extremities, 
migraine and low BP. 33-35 Ocular vasospastic episodes have 
been related to glaucoma. 33,34 Disturbances in BF to the ONH 
seem to occur in some glaucoma patients as a results of 
episodic local vasospasms. 36 Moreover, systemic vasospasmic 
manifestations have been associated to glaucomatous 
deterioration. 37-40 Nicolela et al. 37 concluded in their study 
that glaucoma patients with evidence of vasospasmic effects 
in their extremities were more likely to show visual field 
deterioration after cooling stimulus than glaucoma patients 
without acral vasospasm. Hence, suggesting that vasospastic 
responses may be involved in glaucomatous progression.
Vasospasm of the brain vessels is linked to the pathogenesis 
of migraine. 38 Migraine, a condition more commonly 
encountered in females, has a well documented association 
with glaucoma progression. 39,40 In their respective studies, 
McKendrick et al. and the Collaborative Normal-Tension 
Glaucoma Study Treatment Group found that migraine is an 
independent risk factor for the progression of glaucomatous 
visual À eld loss. 39,41 Furthermore, Drance et al. 42 concluded 
from their visual À eld data collection analysis of 160 patients 
with normal tension glaucoma (NTG) that the occurrence of 
migraine in conjunction with NTG was more common in 
women. However, the study also concluded that gender and 
presence of migraine contribute separately to the risk of 
progression of visual field loss. 42 Low BP has also been 
associated with vasospasm and considered a risk factor in 
glaucoma. 33,35 However, low systemic pressure related to 
glaucoma may or may not be secondary to vasospasm. Pache 
et al. 43 concluded in their study that vasospasm and low BP 
may be separate risk factors for glaucomatous damage. 
Nonetheless, it is a general agreement that non-physiologic 
nocturnal systemic pressure dipping causing marked 
circadian Á uctuations in ocular PP is linked to vasospasm 
and glaucoma progression. 44-46
This evidence suggests that vasospasm may represent a 
particular way by which glaucomatous damage can occur. 
Seemingly, an environment of dysregulated blood Á ow may 
result from these episodes, thus putting the ONH at a greater 
risk of ischemic damage. 34 Furthermore, vasospasm may play 
a more significant role in POAG ONH damage than 
atherosclerosis. Atherosclerotic patients tend to overcome 
with more proÀ cient autoregulation function the challenges 
of ocular perfusion. 18 OBF Á uctuates more dramatically in 
vasospastic patients due their susceptible hyper-responsiveness 
to cold stimuli and emotional stress, which may as well lead 
to reperfusion damage to the ONH. 18,33,47
Vascular endothelial dysfunction
Endothelial vascular dysfunction is also implicated in the 
autoregulatory pathophysiology associated to POAG. 47 
Endothelial biochemical alterations initiated by oxidative 
stress are known to alter the vascular tone and destabilize 
vascular regulation function. 48 Nitric oxide (NO) and 
endothelin-1 (ET-1) are the endothelial vasoactive mediators 
that sustain the physiological balance between vasodilator 
and vasoconstrictor pathways, respectively. 49,50 NO is made 
available via endothelial cell synthesis and endothelin-B 
receptor (ETB) stimulation. 12 ETB receptors activity is 
triggered through interaction with ET-1 that is synthesized 
and released by endothelial cells. ET-1 interacts primarily 
with endothelin-A receptor to mediate physiological 
vasoconstriction. A decrease in the biosynthesis and/or 
bioavailability of NO and an excess of ET-1 causes altered 
vasoreactivity (increased vasoconstriction), which leads to 
an imbalance in basal vascular tone. 47,51
A number of vascular diseases that potentially contribute 
to the development and progression of POAG are 
associated with endothel ium-dependent altered 
vasoreactivity. 12 Dyslipidemia for example, has been 
associated with inhibition of endothelial NO signaling in 
many organs including the eye. Kawakami et al. 52 
demonstrated in a study performed in mice that 
apolipoprotein CIII in hyperlipidemia impairs insulin 
uptake by endothelial cells, necessary for the production 
of NO. A similar study demonstrated that mice lacking 
nitric oxide synthase (NOS), the enzyme present in 
endothelial cells that mediates the conversion of the 
amino acid L-argenine to NO, had hyperlipidemia. 53 
Likewise, faulty ET-1 activity provoking pathological 
vasoconstriction has been identiÀ ed in conditions such as 
hypertension and diabetes. 54,55
A series of studies have investigated the role of endothelial 
mediators in POAG. It has been demonstrated that 
intravenous administration of ET-1 reduces significantly 
retinal blood flow. 56 From their study based on IOP 
increments in living isolated rat retinas, Rigosi et al. 57 
suggest that prolonged or recurrent IOP elevation may 
induce ET-1-mediated retinal capillary dysregulation 
contributing to neuronal damage overtime.
In a study evaluating glaucomatous field progression in 
31 patients with POAG, speciÀ c radioimmunoessay revealed 
that 16 of these patients had increased ET-1 plasma levels. 58 
Another study observing the effect of dual endothelin receptor 
blockage on OBF reveals that oral administration of bosetan, a 
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dual endothelin receptor antagonist, increases ocular blood 
Á ow in patients with POAG. 59
Polak et al. 60 demonstrated in their study on NOS inhibition 
of the ocular vasculature that patients with POAG yielded 
signiÀ cantly less percent reduction of blood Á ow to the ONH 
than healthy controls. Furthermore, the gene expression of 
NOS may be of significance in some glaucoma patients. 
Logan et al. 61 found in their study a statistical signiÀ cant 
difference in the distribution of allele frequencies of a 
speciÀ c NOS gene isoform, between subjects with glaucoma 
that had a history of migraine and control subjects. Other 
studies on the NOS-mediated L-arginine-NO pathway in eyes 
of patients with POAG suggest that the pathway is genetically 
defective. 31,62
Altered endothelial vasoreactivity may be a determinant 
in the development and progression of POAG. However, the 
speciÀ c involvement of endothelial mediators such as ET-1, 
and NOS in the autoregulatory pathophysiology of POAG has 
yet to be completely elucidated. Nonetheless, it appears 
endothelial dysfunction, either primary or secondary to 
vascular diseases, contributes to POAG pathology.
Conclusion
Clearly, POAG is a progressive optic neuropathy that has a 
multi-factorial etiology, in which elevated IOP is the most 
important risk factor. Yet, research evidence and clinical 
experience clearly indicates that elevated IOP alone is not 
at work here. Research observations on altered corneal 
biomechanics and vascular dysregulation in association to 
elevated IOP suggest their possible contribution to the 
disease process. Comparing the two factors, however, it 
appears altered autoregulation function has a more positive 
correlation with POAG. A relatively strong association exists 
between decreased ocular PP precipitated by elevated IOP 
and decrease OBF in patients with vascular regulatory 
dysfunction. 12 However, the exact pathophysiological 
mechanism of how this provokes glaucomatous damage still 
remains uncertain. 16
Research data on corneal biomechanics appears to be a 
bit more contending. While results demonstrate consistent 
lower CH and CRF values in patients with POAG, 3,13 further 
longitudinal studies may be needed to determine if indeed 
in vivo CH and CRF values are independent predictors of 
glaucoma susceptibility. Besides, the possibility remains 
that alterations in corneal biomechanics may be a resultant 
of POAG rather than a risk factor. 6
In conclusion, POAG pathogenesis is a topic that warrants 
further pathophysiological studies to elucidate what risk 
factors other than elevated IOP are relevant for the 
development and progression of the disease. Certainly, 
vascular dysregulation and alterations in corneal 
biomechanics are factors to consider in POAG pathogenesis. 
Hopefully, future glaucoma research will determine more 
speciÀ c variables which may further clarify their correlation 
with the disease process.
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